3. Improving drug safety

How to avoid the risks of drugs in routine care?

Despite careful clinical testing of new drugs, uncertainties about their safety remain even after market approval. This applies, for example, to unknown risks in persons who are often excluded or underrepresented in clinical trials, such as pregnant women, children, or older persons. In the case of already known risks, the question is whether these risks are adequately considered by prescribers and whether recommendations for risk minimization are followed. Based on our pharmacoepidemiological research database GePaRD, which contains data from statutory health insurance providers and thus reflects the real-world setting, we investigate drug safety in routine care. A particular focus of our research is on drug utilization and safety during pregnancy. In addition, we conduct studies requested by health authorities, often in collaboration with international partners.